InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.038 0.001 (1.35%)+
Announcement
Release
19 Aug 2026 8:20AM
Price at Release
$0.037
Full Release
download
Summary
Entropy Neurodynamics Limited has entered into a strategic agreement with BioCina, a TGA-licensed contract development and manufacturing organization, to produce TRP-8803, an IV-infused psilocin formulation, under GMP conditions. This partnership marks a significant step in supporting the international Phase 2/3 clinical trials and the eventual global commercialization of TRP-8803. BioCina’s facilities in Perth and Adelaide will be utilized for the production, designed to meet FDA and EMA standards, ensuring consistent and scalable manufacturing capabilities. This collaboration also helps Entropy maintain full intellectual property rights while preparing for regulatory submissions in major markets including the US and Europe.
Key Points
  • Entropy Neurodynamics Limited signed a strategic agreement with BioCina to manufacture TRP-8803.
  • BioCina will provide GMP manufacturing capabilities for TRP-8803 for Phase 2/3 trials.
  • The agreement supports the international development and commercialization of TRP-8803.
  • BioCina’s facilities in Perth and Adelaide will be used for manufacturing.
  • TRP-8803 is positioned for rapid progression into international trials.
  • The agreement includes manufacturing of GMP clinical drug supply and generation of key data.
  • Entropy retains full ownership of TRP-8803 intellectual property under the agreement.
  • The manufacturing will be done using Cytiva SA25 robotic aseptic filling line.
  • The manufacturing program is expected to take 24 weeks with stability studies continuing for 24 months.
  • The manufacturing capacity can be leveraged across Entropy’s full TRP-8803 development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.